抗微生物活性的 Murepavadin 对来自美国、欧洲和中国的铜绿假单胞菌临床分离株的测试。
Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China.
机构信息
JMI Laboratories, North Liberty, Iowa, USA
Polyphor Ltd., Allschwil, Switzerland.
出版信息
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00311-18. Print 2018 Jul.
Abstract
Murepavadin (formerly POL7080), a 14-amino-acid cyclic peptide, and comparators were tested by the broth microdilution method against 1,219 isolates from 112 medical centers. Murepavadin (MIC, 0.12/0.12 mg/liter) was 4- to 8-fold more active than colistin (MIC, 1/1 mg/liter) and polymyxin B (MIC, 0.5/1 mg/liter) and inhibited 99.1% of isolates at ≤0.5 mg/liter. Only 4 isolates (0.3%) exhibited murepavadin MICs of >2 mg/liter. Murepavadin was equally active against isolates from Europe, the United States, and China.
摘要
Murepavadin（前身为 POL7080）是一种 14 个氨基酸的环肽，与对照药物一起通过肉汤微量稀释法对来自 112 个医疗中心的 1219 株分离株进行了检测。Murepavadin（MIC，0.12/0.12mg/L）的活性比黏菌素（MIC，1/1mg/L）和多黏菌素 B（MIC，0.5/1mg/L）高 4 至 8 倍，对≤0.5mg/L 的分离株的抑制率达到 99.1%。只有 4 株（0.3%）分离株的 murepavadin MIC 大于 2mg/L。Murepavadin 对来自欧洲、美国和中国的分离株具有相同的活性。
相似文献
1
Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China.抗微生物活性的 Murepavadin 对来自美国、欧洲和中国的铜绿假单胞菌临床分离株的测试。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00311-18. Print 2018 Jul.
2
Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.抗当代（2016-17 年）广泛耐药铜绿假单胞菌临床分离株的美罗培南活性检测。
J Antimicrob Chemother. 2018 Sep 1;73(9):2400-2404. doi: 10.1093/jac/dky227.
3
Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics.从囊性纤维化患者中分离出的铜绿假单胞菌对美罗培南和 13 种对照抗生素的敏感性。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01541-19.
4
Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.美国最佳耐药性监测计划国际网络四年（2012年至2015年）期间铜绿假单胞菌的抗菌药敏结果
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02252-16. Print 2017 Mar.
5
Murepavadin: a new antibiotic class in the pipeline.美罗培南：研发管线中的新型抗生素类别。
Expert Rev Anti Infect Ther. 2018 Apr;16(4):259-268. doi: 10.1080/14787210.2018.1441024. Epub 2018 Feb 21.
6
Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane.黏菌素通过靶向细胞质膜中的脂多糖杀死细菌。
Elife. 2021 Apr 6;10:e65836. doi: 10.7554/eLife.65836.
7
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).头孢洛扎/他唑巴坦对亚太地区（不包括中国、澳大利亚和新西兰）引起的医疗保健相关感染的耐药肠杆菌科和铜绿假单胞菌的活性：来自抗菌监测计划（2013-2015 年）的报告。
Int J Antimicrob Agents. 2018 Feb;51(2):181-189. doi: 10.1016/j.ijantimicag.2017.09.016. Epub 2017 Oct 6.
8
Mutations in Confer Cross-Resistance between the LptD Inhibitor POL7080 and Colistin in .突变使 LptD 抑制剂 POL7080 和多粘菌素在 中产生交叉耐药性。
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00511-19. Print 2019 Sep.
9
Murepavadin antimicrobial activity against and resistance development in cystic fibrosis Pseudomonas aeruginosa isolates.米卡芬净对囊性纤维化铜绿假单胞菌分离株的抗菌活性和耐药性发展。
J Antimicrob Chemother. 2021 Mar 12;76(4):984-992. doi: 10.1093/jac/dkaa529.
10
Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.纸片扩散法、Etest法和肉汤微量稀释法检测耐碳青霉烯类铜绿假单胞菌对多黏菌素敏感性的比较。
Ann Clin Microbiol Antimicrob. 2007 Aug 15;6:8. doi: 10.1186/1476-0711-6-8.
引用本文的文献
1
Antimicrobial peptides: a promising frontier to combat antibiotic resistant pathogens.抗菌肽：对抗抗生素耐药病原体的一个有前景的领域。
Ann Med Surg (Lond). 2025 Mar 27;87(4):2118-2132. doi: 10.1097/MS9.0000000000003106. eCollection 2025 Apr.
2
The role of artificial intelligence and machine learning in predicting and combating antimicrobial resistance.人工智能和机器学习在预测及对抗抗菌药物耐药性方面的作用。
Comput Struct Biotechnol J. 2025 Jan 18;27:423-439. doi: 10.1016/j.csbj.2025.01.006. eCollection 2025.
3
Understanding the pathophysiology of colonization as a guide for future treatment for chronic leg ulcers.了解定植的病理生理学，为慢性腿部溃疡的未来治疗提供指导。
Burns Trauma. 2025 Jan 18;13:tkae083. doi: 10.1093/burnst/tkae083. eCollection 2025.
4
Murepavadin Enhances the Killing Efficacy of Ciprofloxacin against by Inhibiting Drug Efflux.穆雷帕瓦定通过抑制药物外排增强环丙沙星对……的杀菌效力。 （原文中“against”后缺少具体对象）
Antibiotics (Basel). 2024 Aug 26;13(9):810. doi: 10.3390/antibiotics13090810.
5
Structural Insights into the Lipopolysaccharide Transport (Lpt) System as a Novel Antibiotic Target.脂多糖转运（Lpt）系统的结构见解作为一种新的抗生素靶标。
J Microbiol. 2024 Apr;62(4):261-275. doi: 10.1007/s12275-024-00137-w. Epub 2024 May 31.
6
Synthesis of the Antimicrobial Peptide Murepavadin Using Novel Coupling Agents.使用新型偶联剂合成抗菌肽 Murepavadin。
Biomolecules. 2024 Apr 27;14(5):526. doi: 10.3390/biom14050526.
7
Murepavadin promotes the killing efficacies of aminoglycoside antibiotics against by enhancing membrane potential.Murepavadin 通过增强膜电位提高氨基糖苷类抗生素对 的杀伤效力。
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0153923. doi: 10.1128/aac.01539-23. Epub 2024 Mar 12.
8
Mutations in genes , , and impair the susceptibility of cystic fibrosis strains of to murepavadin.基因突变 、 和 会降低囊性纤维化菌株对 murepavadin 的敏感性。
Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0129823. doi: 10.1128/aac.01298-23. Epub 2023 Dec 11.
9
Resistance is futile: targeting multidrug-resistant bacteria with Cys-rich cyclic polypeptides.抵抗是徒劳的：用富含半胱氨酸的环肽靶向多重耐药细菌。
RSC Chem Biol. 2023 Aug 21;4(10):722-735. doi: 10.1039/d3cb00015j. eCollection 2023 Oct 4.
10
Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of .多重耐药/广泛耐药临床病原体中的抗生素耐药时代 。（原文句子不完整，翻译可能不太准确，你可补充完整原文后再让我翻译）
Pharmaceuticals (Basel). 2023 Aug 30;16(9):1230. doi: 10.3390/ph16091230.
本文引用的文献
1
Pharmacokinetics and Safety of Intravenous Murepavadin Infusion in Healthy Adult Subjects Administered Single and Multiple Ascending Doses.静脉注射莫奈拉韦输注在健康成年受试者中单次和多次递增剂量的药代动力学和安全性。
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02355-17. Print 2018 Apr.
2
New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?新型革兰氏阴性菌感染治疗药物：重现奇迹还是虚幻曙光？
Clin Microbiol Infect. 2017 Oct;23(10):704-712. doi: 10.1016/j.cmi.2017.09.001. Epub 2017 Sep 8.
3
What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.就耐药性和药效学原理而言，我们对正在研发的新型抗菌药物有何期待。
J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):113-132. doi: 10.1007/s10928-017-9506-4. Epub 2017 Feb 4.
4
Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.美国最佳耐药性监测计划国际网络四年（2012年至2015年）期间铜绿假单胞菌的抗菌药敏结果
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02252-16. Print 2017 Mar.
5
Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.与医疗保健相关感染有关的耐抗菌性病原体：2011 - 2014年向疾病控制与预防中心国家医疗保健安全网络报告的数据摘要
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288-1301. doi: 10.1017/ice.2016.174. Epub 2016 Aug 30.
6
Targeted Treatment for Bacterial Infections: Prospects for Pathogen-Specific Antibiotics Coupled with Rapid Diagnostics.细菌感染的靶向治疗：病原体特异性抗生素与快速诊断相结合的前景
Tetrahedron. 2016 Jun 23;72(25):3609-3624. doi: 10.1016/j.tet.2015.09.069. Epub 2015 Oct 9.
7
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012.2009-2012 年美国和欧洲医院住院肺炎患者分离的革兰氏阴性菌的抗菌药物敏感性：来自 SENTRY 抗菌监测计划的结果。
Int J Antimicrob Agents. 2014 Apr;43(4):328-34. doi: 10.1016/j.ijantimicag.2014.01.007. Epub 2014 Feb 7.
8
Investigational antimicrobial agents of 2013.2013 年的研究性抗菌药物。
Clin Microbiol Rev. 2013 Oct;26(4):792-821. doi: 10.1128/CMR.00033-13.
9
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.耐多药、广泛耐药和全耐药细菌：获得性耐药的国际专家临时标准定义建议
Clin Microbiol Infect. 2012 Mar;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. Epub 2011 Jul 27.
10
Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa.肽模拟抗生素靶向铜绿假单胞菌的外膜生物发生。
Science. 2010 Feb 19;327(5968):1010-3. doi: 10.1126/science.1182749.
Zotero 插件